Trump Must Be ‘Harsh’ With Big Pharma, Says Icelandic Drugmaker

If the US wants to see lower drug prices, it should make it easier for cheaper copies of expensive biologic drugs to enter the market, Alvotech SA Chief Executive Officer Robert Wessman said.

Enabling more competition from companies producing such biosimilar copies of older medicines would save a significant amount of money, the founder of the Iceland-based biosimilar maker said in an interview.